Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
2011

Identifying a New Target for Pancreatic Cancer Immunotherapy

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y

Primary Institution: Kumamoto University, Kumamoto, Japan

Hypothesis

Can KIF20A be a potential target for anticancer immunotherapy in pancreatic cancer?

Conclusion

KIF20A is a novel promising candidate for anticancer immunotherapeutic target for pancreatic cancers.

Supporting Evidence

  • KIF20A was overexpressed in pancreatic cancer tissues but not in normal tissues.
  • Three specific peptides from KIF20A were able to induce CTLs in HLA-A2 transgenic mice.
  • Human CTLs generated from healthy donors showed cytotoxic responses to cancer cells expressing KIF20A.

Takeaway

Researchers found a new protein called KIF20A that is mostly found in pancreatic cancer cells, which could help create better treatments for this disease.

Methodology

The study used genome-wide cDNA microarray analysis and HLA-A2 transgenic mice to identify CTL epitopes of KIF20A.

Potential Biases

Potential bias in sample selection as tissues were obtained from a single institution.

Limitations

The study primarily focused on HLA-A2 positive individuals, which may limit the applicability of findings to other populations.

Participant Demographics

The study involved 14 patients with pancreatic cancer and healthy donors for PBMCs.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606052

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication